Zenas BioPharma, Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
At close
$25.11
−$1.24 (−4.70%) Close
Pre-market$26.33
+$1.22 (+4.85%) 1:26 AM ET
Prev closePrevC$26.35
OpenOpen$26.28
Day highHigh$26.28
Day lowLow$25.11
VolumeVol18
Avg volAvgVol803,594
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.41B
P/E ratio
1.84
FY Revenue
$15.00M
EPS
13.67
Gross Margin
100.00%
Sector
Healthcare
AI report sections
MIXED
ZBIO
Zenas BioPharma, Inc.
Zenas BioPharma exhibits very strong recent price performance with multiple bullish technical breakouts while trading in the upper portion of its 52-week range. At the same time, fundamentals show minimal revenue, very large operating losses, and deeply negative free cash flow, alongside elevated short interest and predominantly negative legal-focused news flow.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO
Pomerantz LLP is investigating potential securities fraud claims against Zenas BioPharma following disappointing Phase 3 trial results for obexelimab in IgG4-RD announced on January 5, 2026. Despite the company characterizing results as 'positive,' analysts noted the drug's efficacy fell short of commercial viability thresholds. The stock declined 51.86% on the announcement and another 8.49% the following day after the CEO acknowledged disappointment with the trial's hazard ratio metric.
Company faces securities fraud investigation following misleading characterization of disappointing Phase 3 trial results. Stock price collapsed 51.86% on announcement and declined further 8.49% after CEO acknowledged the drug's efficacy fell short of expectations, indicating significant investor losses and potential corporate misconduct.
NegativeGlobeNewswire Inc.• Pomerantz Llp
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
Pomerantz LLP announced investigations into securities fraud claims on behalf of investors in three biotech companies. Zenas BioPharma's stock plummeted 51.86% following disappointing Phase 3 trial results for obexelimab, with the CEO acknowledging the drug's efficacy fell short of expectations, triggering an additional 8.49% decline. Similar investigations were initiated for Instil Bio and Corcept Therapeutics.
Company issued misleading characterization of Phase 3 trial results as 'positive' when efficacy fell short of commercial viability thresholds. Stock declined 51.86% on announcement and another 8.49% when CEO acknowledged disappointment with results. Securities fraud investigation initiated.
PositiveThe Motley Fool• Cory Renauer
Chairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948
Leon O. Moulder, CEO of Zenas BioPharma, purchased 36,928 shares through an open-market transaction and announced a licensing deal with InnoCare Pharma for a multiple sclerosis candidate, signaling confidence in the company's potential.
CEO's stock purchase, ongoing clinical trials, licensing deal with InnoCare Pharma, and potential for future buyout based on founder's previous successful biotech exit
NegativeGlobeNewswire Inc.• N/A
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
Pomerantz LLP has filed a class action lawsuit against Zenas BioPharma, Inc. (ZBIO) due to potential securities fraud or unlawful business practices. The lawsuit is related to Zenas's initial public offering in September 2024, where the company allegedly misrepresented its ability to fund operations.
ZBIOZenas BioPharmaclass action lawsuitsecurities fraudinitial public offering
Sentiment note
The article indicates that Zenas BioPharma is facing a class action lawsuit due to potential securities fraud or unlawful business practices related to its IPO, which has resulted in a sharp decline in its stock price and losses for investors.
NegativeGlobeNewswire Inc.• Faruqi & Faruqi, Llp
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. (ZBIO) for making false and/or misleading statements regarding the company's ability to fund its operations using existing cash and expected net proceeds from the IPO.
ZBIOZenas BioPharmasecurities class actionIPO
Sentiment note
The article indicates that Zenas BioPharma is being investigated for making false and/or misleading statements about its ability to fund operations, which could have led to investor losses.
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
A class action lawsuit has been filed against Zenas BioPharma, Inc. alleging that the company's IPO registration statement contained false and/or misleading statements about its ability to fund operations.
The article alleges that Zenas BioPharma made false and/or misleading statements in its IPO registration statement, which could lead to substantial losses for investors.
NegativeGlobeNewswire Inc.• N/A
Zenas BioPharma, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; June 16, 2025 Deadline to file Lead Plaintiff Motion
Zenas BioPharma, Inc. is facing a class action lawsuit alleging that the company's IPO offering documents were materially false, misleading, or omitted material information by overstating the length of time the company could fund its operations.
ZBIOZenas BioPharmaclass action lawsuitIPOmisleading information
Sentiment note
The company is facing a class action lawsuit alleging that its IPO offering documents were materially false and misleading, which led to investor losses.
NeutralGlobeNewswire Inc.• N/A
GoHealth, Inc. Investor News: If You Have Suffered Losses in GoHealth, Inc. (NASDAQ: GOCO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
GoHealth, Inc. is facing a potential securities class action lawsuit due to allegations that the company may have issued materially misleading business information to the investing public. The lawsuit is being investigated by the Rosen Law Firm.
GOCOELVZBIOGoHealthsecurities class actioninvestor losses
Sentiment note
The article mentions that the Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. to secure counsel before an important deadline in a securities class action, but does not provide any specific details about the case or the company's situation.
NegativeGlobeNewswire Inc.• N/A
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and Avis Budget and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is reminding investors of class action lawsuits filed against Ibotta, NET Power, Zenas BioPharma, and Avis Budget, with deadlines for investors to become lead plaintiffs.
The article states that the complaint alleges Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO.
NegativeGlobeNewswire Inc.• N/A
Zenas BioPharma, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; June 16, 2025 Deadline to file Lead Plaintiff Motion
Zenas BioPharma, Inc. is facing a class action lawsuit alleging that the company's IPO offering documents were materially false, misleading, or omitted material information by overstating the length of time the company could fund its operations.
ZBIOZenas BioPharmaclass action lawsuitIPOmisleading information
Sentiment note
The company is facing a class action lawsuit alleging that its IPO offering documents were materially false and misleading, which led to investor losses.
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
A class action lawsuit has been filed against Zenas BioPharma, Inc. alleging that the company's IPO registration statement contained false and/or misleading statements about the company's ability to fund its operations.
The article alleges that Zenas BioPharma made false and/or misleading statements in its IPO registration statement, which could lead to substantial losses for investors.
NegativeGlobeNewswire Inc.• The Gross Law Firm
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Zenas BioPharma, Inc. (ZBIO) Shareholders
The Gross Law Firm has filed a securities class action lawsuit on behalf of Zenas BioPharma, Inc. (ZBIO) shareholders, alleging that the company materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO.
ZBIOZenas BioPharmasecurities class actionIPO
Sentiment note
The article alleges that Zenas BioPharma materially overstated the amount of time it would be able to fund its operations, which suggests potential financial issues or misrepresentation of the company's financial position.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
